trending Market Intelligence /marketintelligence/en/news-insights/trending/bLccV003D_JsQo5ZYXdT2w2 content esgSubNav
In This List

Ryvu Therapeutics to start trading on Warsaw exchange after Selvita split

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Ryvu Therapeutics to start trading on Warsaw exchange after Selvita split

Selvita SA said Ryvu Therapeutics will likely start trading on the Warsaw Stock Exchange under the ticker symbol RVU on or around Oct. 9 after its spinoff was recognized by the National Court Register of Poland.

The registration of Ryvu Therapeutics' shares is subject to approvals from the National Depository for Securities and the Warsaw Stock Exchange. Until then, the value of both companies will reflect under the current listing on the exchange.

Shareholders of Selvita, a contract research organization, approved the separation Sept. 19. Both companies will operate independently and will have separate executive teams, Krakow, Poland-based Selvita noted in its Oct. 1 press release.

Ryvu is a clinical-stage biopharmaceutical company that focuses on developing small molecule therapies for cancer treatment.

Selvita expects to start trading on or around Oct. 16 under the ticker symbol SLV.